tiragolumab
Showing 1 - 25 of 39
Carcinoma, Hepatocellular Trial (Atezolizumab, Bevacizumab, Tiragolumab)
Not yet recruiting
- Carcinoma, Hepatocellular
- Atezolizumab
- +3 more
- (no location specified)
Jun 14, 2023
NSCLC Trial (Atezolizumab, Tiragolumab)
Not yet recruiting
- Non-small Cell Lung Cancer
- Atezolizumab
- Tiragolumab
- (no location specified)
Apr 11, 2023
Urothelial Cancer Trial in Beijing (Atezolizumab, RO7247669, Tiragolumab)
Recruiting
- Urothelial Cancer
- Atezolizumab
- +2 more
-
Beijing, ChinaBeijing Cancer Hospital
Jan 18, 2023
Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial (biological, procedure, drug)
Not yet recruiting
- Advanced Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Atezolizumab
- +5 more
- (no location specified)
Feb 4, 2023
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma Trial in Houston (drug, behavioral, radiation)
Not yet recruiting
- Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Tiragolumab
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Locally Advanced Esophageal Squamous Cell Carcinoma Trial (Tiragolumab)
Not yet recruiting
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Tiragolumab
- (no location specified)
Feb 23, 2023
NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tiragolumab
- +3 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Feb 16, 2023
Stomach Tumors, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Tiragolumab, Oxaliplatin)
Active, not recruiting
- Stomach Neoplasms
- +2 more
- Atezolizumab
- +3 more
-
Beijing, China
- +10 more
Dec 21, 2022
Small Cell Lung Carcinoma Trial in China (Tiragolumab, Atezolizumab, Carboplatin)
Active, not recruiting
- Small Cell Lung Carcinoma
- Tiragolumab
- +4 more
-
Beijing, China
- +15 more
Aug 15, 2022
Metastatic Malignancy Trial in Houston (Atezolizumab, Tiragolumab)
Not yet recruiting
- Metastatic Malignancy
- Atezolizumab
- Tiragolumab
-
Houston, TexasM D Anderson Cancer Center
Dec 19, 2022
Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma Trial in Korea, Republic of, United States (Tiragolumab,
Active, not recruiting
- Multiple Myeloma
- +2 more
- Tiragolumab
- +3 more
-
Denver, Colorado
- +12 more
Jan 19, 2023
Carcinoma, Small Cell Lung Trial in China (Atezolizumab, Tiragolumab, Placebo)
Active, not recruiting
- Carcinoma, Small Cell Lung
- Atezolizumab
- +2 more
-
Beijing City, China
- +20 more
Dec 15, 2022
Triple-Negative Breast Cancer Trial in Worldwide (Tiragolumab, Atezolizumab, Nab-paclitaxel)
Active, not recruiting
- Triple-Negative Breast Cancer
- Tiragolumab
- +7 more
-
Birmingham, Alabama
- +23 more
Jan 19, 2023
Carcinoma, Hepatocellular Trial (Atezolizumab, Bevacizumab, Tiragolumab)
Not yet recruiting
- Carcinoma, Hepatocellular
- Atezolizumab
- +3 more
- (no location specified)
Jun 15, 2023
Cohort 1 : Metastatic Non Small Cell Lung Cancer, Cohort 2 : Metastatic Bladder Cancer, Cohort 3 : Metastatic Renal Cell
Not yet recruiting
- Cohort 1 : Metastatic Non Small Cell Lung Cancer
- +3 more
- Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]
- +2 more
-
Dijon, Bourgogne, FranceCentre Georges François Leclerc (CGFL)
Feb 18, 2022
Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Worldwide (Mosunetuzumab SC, Tiragolumab, Atezolizumab)
Recruiting
- Non-Hodgkin Lymphoma, Follicular Lymphoma
- Mosunetuzumab SC
- +3 more
-
Ann Arbor, Michigan
- +14 more
Aug 12, 2022
NSCLC, Solid Tumor Trial in United States (Atezolizumab, Chemotherapy (Arm A Only), Tiragolumab)
Recruiting
- Non-Small Cell Lung Cancer
- Solid Tumor
- Atezolizumab
- +2 more
-
Fort Myers, Florida
- +6 more
Feb 16, 2022
Advanced/Metastatic Tumors Trial in Worldwide (Atezolizumab, Tiragolumab, Carboplatin)
Active, not recruiting
- Advanced/Metastatic Tumors
- Atezolizumab
- +9 more
-
Scottsdale, Arizona
- +27 more
Jan 5, 2023
Esophageal Cancer Trial in Worldwide (Atezolizumab, Tiragolumab, Paclitaxel)
Active, not recruiting
- Esophageal Cancer
- Atezolizumab
- +5 more
-
Anyang City, China
- +68 more
Jan 20, 2023
NSCLC (NSCLC) Trial in Worldwide (Atezolizumab, Tiragolumab, Carboplatin)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- Atezolizumab
- +6 more
-
Duarte, California
- +23 more
Aug 8, 2022
NSCLC Trial in Worldwide (Atezolizumab, Tiragolumab, Placebo)
Active, not recruiting
- Non-small Cell Lung Cancer
- Atezolizumab
- +2 more
-
Tempe, Arizona
- +40 more
Nov 11, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +5 more
- Atezolizumab
- +3 more
-
Jacksonville, Florida
- +2 more
Oct 21, 2022